AKT1 and lung carcinoma: Studies have shown that EVO can exert its anti-tumor potential by inhibiting cell proliferation, invasion, and migration, inducing cell apoptosis and senescence through pathways such as phosphoinositide 3-kinase/ protein kinase B (PI3K/AKT) and Notch pathways in cancers such as lung cancer, gastric cancer, and oral cancer [4,18].